** Shares of biopharmaceutical firm Alumis ALMS.O rise 15.5% to $4.36, hitting over one-month high
** ALMS and Tokyo-based Kaken Pharmaceutical 4521.T say they have entered into a licensing agreement to develop, manufacture and commercialize an experimental skin drug in Japan
** ALMS' lead drug candidate, ESK-001, is currently in a late-stage study which aims to fix immune system issues in various diseases caused by inflammatory substances like IL-23, IL-17, and type 1 interferon
** ALMS will receive $40 million in upfront and near-term co-development payments in 2025 to 2026
** The company could earn up to $140 million more based on milestone achievements
** ESK-001 is also being tested in a mid-stage study to treat a type of autoimmune disease called systemic lupus erythematosus
** ALMS has fallen 44.4% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。